pharmaphorum
JUNE 29, 2021
Robert Galarza outlines how blockchain technology can be utilised to verify, validate and standardise the efficacy of medical cannabis and other plant based therapies in clinical trials. . The Chinese surgeon Huo Tuo first mixed powdered cannabis with wine to make an anesthetic sometime between 140 and 208 CE. Indeed, the Chinese term for “anesthesia” (mázui ??
Outsourcing Pharma
JUNE 28, 2021
The companyâs Ryze technology combines a clinical MDR and study automation platform, designed to accelerate and optimize design and execution of trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JUNE 29, 2021
Company initially withdrew a marketing authorisation application for the gene therapy last year
Dr. Jamie Hardy: The Lifestyle Pharmacist
JUNE 27, 2021
Heat stroke and heat exhaustion are serious, life-threatening conditions. More than 600 people in the United States are killed by the extreme heat every year, according to the Centers for Disease Control and Prevention. How to protect yourself from heat exhaustion and heat stroke. Protecting yourself from the dangers of heat exhaustion and heat stroke is a must.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JUNE 29, 2021
Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. The Com-COV trial compared two shots with Pfizer/BioNTech’s Comirnaty, two doses of AstraZeneca’s Vaxzevria, and a mixed regimen of one of each jab, and found that all were effective at stimulating a “robust” immune response against the coronavirus, according to the
Outsourcing Pharma
JUNE 29, 2021
The trial solutions firm is working with Childrenâs Oncology Group to expand in-home research and care options for investigational immune-oncology therapy.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Med Ed 101
JUNE 30, 2021
An 89-year-old female has a history of frequent UTIs. She has been taking ciprofloxacin for UTI prophylaxis at 250 mg once daily for about 1 year. She has not had a UTI since starting on the ciprofloxacin. She takes it in the morning with her breakfast. She has a history of diabetes, CKD, osteoarthritis, neuropathy, […]. The post Ciprofloxacin for UTI Prophylaxis – Case Study appeared first on Med Ed 101.
pharmaphorum
JUNE 28, 2021
Renal diseases represent a formidable challenge on public health systems around the world. They are costly in terms of economic burden and quality of life, especially among older patient populations, and are closely linked to other chronic conditions such as cardiovascular disease and diabetes. Joan Perelló and Adam Levy explore the advancement of treatments in the renal space.
Outsourcing Pharma
JULY 1, 2021
On July 7, a group of seasoned industry leaders will offer insights at Rare/orphan diseases, special patient population, a focused, free online event.
Pharma Times
JUNE 29, 2021
Mixing different vaccines produces a strong immune response against virus, according to researchers
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Med Ed 101
JUNE 27, 2021
In this article, we take a look at the Alpha-2 Adrenergic Agonists. In comparing Alpha-2 Adrenergic Agonists, we will primarily look at dosing, adverse effects, and notable indications. Clonidine is FDA-approved for attention deficit hyperactivity disorder (ADHD), cancer pain, and hypertension. It is also used off-label for a variety of reasons, such as hot sweats, […].
pharmaphorum
JUNE 28, 2021
The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the body has yielded impressive results in patients with ATTR amyloidosis, a life-threatening rare disease. . Preliminary results from a phase 1 trial run by Regeneron and CRISPR specialist Intellia Therapeutics – co-founded by Nobel Prize winner Jennifer Doudna – showed steep reductions in a biomarker of ATTR amyloidosis disease activity with a single dose of the NTLA-2001 drug.
Outsourcing Pharma
JULY 1, 2021
Thanks in part to the recent completion of an $8m investment, 2020 On-site plans to expand its services, including the mobile support of vision research.
Pharma Times
JUNE 29, 2021
Sanofi is currently collaborating with Translate Bio on a mRNA-based COVID-19 vaccine candidate
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 1, 2021
From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve outcomes for patients in need. In today’s feature, Dr. Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality. . Only a year after the emergence of COVID-19, a handful of life science companies started publishing data on the encouragingly high efficacy of their vaccine candidates.
pharmaphorum
JUNE 27, 2021
AstraZeneca and Oxford University have started dosing patients in a trial of a new version of their COVID-19 vaccine that is designed to target the beta or South African variant of the SARS-CoV-2 virus. The beta variant – also known as B.1.351 – is estimated to be around 50% more transmissible than earlier strains of SARS-CoV-2, but seems to be able to evade the antibodies generated by current COVID-19 vaccines including AZ’s current Vaxzevria (AZD1222) shot.
pharmaphorum
JULY 2, 2021
AstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction (HFpEF), showing it worked as expected but wasn’t able to provide any clinical benefit to patients. . Daily doses of AZD4831 were able to reduce the activity of myeloperoxidase (MPO), an enzyme linked to tissue and blood vessel damage due to inflammation and scar tissues formation (fibrosis) in models of cardiovascular disease, by 69% after 30 days in the phase 2a SATELLITE stu
pharmaphorum
JUNE 30, 2021
Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . It’s a big disappointment for Altimmune, which said back in February that it was hoping to find a more convenient alternative to injected COVID-19 vaccines – and one which would be stable at room temperature, making distribution and delivery easier.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JUNE 30, 2021
Pharma has both an opportunity and a responsibility to do its part in tackling climate change – and the time to act is now, according to speakers at a recent event. Amanda Barrell reports. The pharma industry has clearly stated its commitment to a net zero future, but where are we on that journey, what else can be done, and could organisations achieve more if they worked together?
pharmaphorum
JULY 2, 2021
Zydus Cadila has filed for emergency use approval (EUA) in India of its plasmid DNA-based vaccine for COVID-19, which if given a green light could become the first shot of its type to be cleared for widespread use in humans. . Leaving aside the possible technological milestone, the ZyCOV-D vaccine has a few characteristics that could stand in the way of its rollout, including a need for three doses, whereas all India’s current vaccines only need two.
pharmaphorum
JULY 1, 2021
Merck KGaA has joined forces with a unit of medtech firm B Braun – neuroloop – on a way to treat inflammatory diseases using neurostimulator devices. The German drugmaker will work with startup neuroloop on bioelectronics , put simply the harnessing of electrical stimulation to treat human disease, with a focus on chronic conditions like arthritis and inflammatory bowel disease. neuroloop – a spinout of Freiburg University in Germany formed in 2016 – has been working to date on using its device
pharmaphorum
JUNE 28, 2021
Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after reporting mixed results in a phase 3 trial in liver cancer. The COSMIC-312 study is comparing Cabometyx (cabozantinib) given alongside Roche’s cancer immunotherapy Tecentriq (atezolizumab) to Bayer’s Nexavar (sorafenib) as a first-line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer.
pharmaphorum
JULY 1, 2021
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, infectious diseases, and rare, undertreated indications.
pharmaphorum
JUNE 29, 2021
Patient recruitment has begun in a National Institutes of Health (NIH) trial of two digital therapeutics (DTx) for people with opioid use disorder (OUD), developed by Pear Therapeutics and Chess Health. . The CTN-0100 study is test strategies to help keep people with OUD on drug treatment, improve the chances that those stabilised with drug treatments for OUD can come off medication without relapsing, as well as to find ways to predict the risk of relapse based on patient characteristics.
pharmaphorum
JUNE 30, 2021
The University of Manchester has formed a joint venture with Morningside to carry out clinical trials of various digital health technologies developed by the investment group’s portfolio companies. . Health Innovation Manchester and its Academic Health Science Centre are also participating in the JV, which will focus on digital diagnostics and interventions that could play a role in prevention and early detection of disease and helping more patients to receive treatment outside the hospita
pharmaphorum
JULY 1, 2021
Introduction. The clinical trial process is a long, expensive, complicated one that often ends in failure. This means that to have a successful outcome, careful decision making and planning are absolutely essential. And so are data standards! The FDA requires clinical study data to be submitted in a standardized format. This allows the FDA to receive, process, review and archive submissions efficiently.
pharmaphorum
JULY 1, 2021
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive. . The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination push, and then be expanded to include all adults aged 50 and over, plus younger, at-risk people who qualify for a flu shot.
pharmaphorum
JULY 2, 2021
Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. Under the terms of the new deal, Nestle’s Health Sciences unit will pay Seres another $125 million if the FDA approves the drug – called SER-109 – and is also line for up to $225 million in commercial milestones tied to sales targets.
pharmaphorum
JUNE 29, 2021
Artificial intelligence (AI) has the potential to improve the delivery of healthcare, but only if ethics and human rights are put at its heart of its design and use, according to the World Health Organisation (WHO). Digital technologies and AI are already being deployed to improve the speed and accuracy of diagnosis and screening for diseases, assist with clinical care, support R&D, and guide public health policy, according to a just-published WHO document called Ethics and governance of art
pharmaphorum
JULY 1, 2021
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on the drug last month, and a swift update to its deliberations won’t be much comfort to the company. The cost-effectiveness watchdog has revised its calculation of a fair price range for Aduhelm (aducanumab) upwards, but only by a small amount.
pharmaphorum
JUNE 30, 2021
Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side-effect profile than current therapies. The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to tolerability issues with the current generation of antipsychotic drugs.
Outsourcing Pharma
JUNE 29, 2021
The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.
Pharma Times
JUNE 29, 2021
The new Code has been updated to reflect changes in the pharma environment
Expert insights. Personalized for you.
130 
Let's personalize your content